Hospira successfully revokes Cubist patents

The English High Court made its decision on the UK Hospira and Cubist Pharmaceuticals patent dispute last Friday, June 10, concluding that three Cubist-owned patents are invalid.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Part II: The race to replace semaglutide heats up

23 March 2026 With Novo Nordisk's core semaglutide patent expired in India last week, the company that built one of the most successful drugs in pharmaceutical history is already fighting on a new front. So what comes next?

Big Pharma

Sandoz strikes fresh biosimilar deal with South Korean biotech

19 March 2026 The Swiss generics giant secures global commercialisation rights as partnership targets multi-billion-dollar loss-of-exclusivity opportunity.

Big Pharma

INTA: ‘New normal’ for in-house counsel as budgets fall

16 March 2026 Research from the International Trademark Association finds in-house counsel taking on more strategic work while facing shrinking budgets, prompting a shift towards alternative billing and greater use of AI.

More features

LSPN Awards USA: Meet the judges

UK patent office adopts EPO standards for AI inventions

Faegre Drinker boosts FDA regulatory practice with two senior hires

Gilead to pay up to $5bn for antibody-drug conjugates push

Closing the women's health gap offers ‘benefits for all’

Bausch reaches deal with competitor over IBS drug generic

European patent offices raise fees

UPC refuses early knockout in Illumina–Element dispute

Hospira successfully revokes Cubist patents

More on this story

Editor's picks

Editor's picks

More features